Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04JFG
|
|||
| Drug Name |
BMS-986253
|
|||
| Synonyms |
Humax-inflam; HuMax-IL8; Humax-IL-8; UNII-N0YWS8X3S9; N0YWS8X3S9; MDX-018; BMS-986253; anti-Il-8 monoclonal antibody humax-IL8; 2231258-73-2
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN interleukin 8 (IL8) | Target Info | Inhibitor | [1], [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04347226) Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19. U.S. National Institutes of Health. | |||
| REF 2 | Induction of IL-8 Release in Lung Cells via Activator protein-1 by Recombinant Baculovirus Displaying Severe Acute Respiratory Syndrome-Coronavirus Spike Proteins: Identification of Two Functional Regions. J Immunol. 2004 Dec 15;173(12):7602-14. doi: 10.4049/jimmunol.173.12.7602. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.